Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Mon, 11th Oct 2021 10:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cadence Minerals PLC, up 42% at 24.65 pence, 12-month range 11.1p-32.49p. Receives confirmation from its secured bank creditors that they have obtained approval from their credit committees for the proposed terms of a settlement agreement, paving the way for Cadence to vest an initial 20% in the Amapa iron ore project in Brazil. A joint venture between Cadence and Indo Sino Trade Pte Ltd will own 99.9% of DEV Mineracao SA, the owner of the Amapa project. "Today's announcement is a landmark for Amapa, both in terms of certainty for DEV employees, the wider Amapa community and for Cadence shareholders," says Chair Andrew Suckling.

----------

Reneuron Group PLC, up 31% at 123.80p, 12-month 70p-153.78p. The biotechnology company reports positive data that provides "clear pre-clinical proof-of-concept" that its novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases. "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain," says Chief Executive Olav Hellebo.

----------

Feedback PLC, up 16% at 0.8432p, 12-month range 0.6p-1.57p. The medical imaging software company signs memorandum of understanding with Quest Teleradiology Solutions - a teleradiology organisation with customers across India, the UK and throughout Africa - to develop strategic opportunities for Bleepa, its clinical communications platform, in the "large and growing" Indian healthcare market, the UK and internationally.

----------

Oracle Power PLC, up 15% at 0.385p, 12-month 0.3p-0.75p. The natural resources project developer signs non-exclusive co-operation agreement with PowerChina International Group Ltd to jointly develop a green hydrogen production facility in Pakistan. It is targeting 400 megawatt capacity hydrogen plant, with planned output of around 150,000 kilograms per day.

----------

AIM - LOSERS

----------

ASOS PLC, down 11% at 2,474p, 12-month range 2,300p-5,994.95p. The online fashion retailer posts jump in annual profit, but warns on year ahead and announces departure of chief executive. Adjusted pretax profit for the 2022 financial year expected between around GBP110 million to GBP140 million. This is well below the GBP193.6 million registered for the financial year just ended. ASOS shakes up board to "underpin delivery of the next phase of its global growth strategy". CEO Nick Beighton is stepping down after 12 years with ASOS, including six as CEO, and a search is underway for his replacement.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2014 05:24

UK AGM, EGM Calendar - Week Ahead

Read more
28 Aug 2014 15:11

UK AGM, EGM Calendar - Week Ahead

Read more
28 Aug 2014 05:31

UK AGM, EGM Calendar - Week Ahead

Read more
27 Aug 2014 15:25

UK AGM, EGM Calendar - Week Ahead

Read more
27 Aug 2014 05:53

UK AGM, EGM Calendar - Week Ahead

Read more
26 Aug 2014 15:16

UK AGM, EGM Calendar - Week Ahead

Read more
25 Jul 2014 09:40

DIRECTOR DEALINGS: ReNeuron Group Directors Buy Shares

Read more
23 Jul 2014 14:17

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

Read more
18 Jun 2014 13:29

ReNeuron well set after 'transformational' year

Stem cell treatment developer ReNeuron lost an increased £7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed compa

Read more
18 Jun 2014 11:47

UK MIDDAY BRIEFING: BOE Policy Makers Still Unanimous

LONDON (Alliance News) - Bank of England policymakers unanimously decided to leave the key interest rates and asset purchase programme unchanged at the monetary policy meeting held on June 4 and 5, the minutes of the meeting showed Wednesday.

All nine members of the Monetary Policy

Read more
18 Jun 2014 08:27

ReNeuron Confident For Future Despite Loss As It Advances Therapies

LONDON (Alliance News) - ReNeuron Group PLC Wednesday expressed confidence in its future as it continued to develop its stem-cell therapies towards commercialisation, and it posted a widened loss in the year to end-March. The company posted a pretax loss of GBP7.8 million, widened from GBP7

Read more
18 Jun 2014 07:21

UK MORNING BRIEFING: Zoopla Prices IPO As Markets Await Central Banks

LONDON (Alliance News) - UK shares have opened higher Wednesday, following a firm close on Wall Street and ahead of central bank announcements in the UK and US.

There was further IPO activity Wednesday, as property website Zoopla Property Group said it will price it

Read more
7 May 2014 14:15

ReNeuron Says Stroke Disability Therapy Study Yielding "Encouraging" Results

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC Wednesday said that its PISCES study of its ReN001 stem cell therapy for stroke disability has continued to yield encouraging results. The company said that there was no cell-related or immunological adverse events report

Read more
23 Apr 2014 12:02

ReNeuron seeks to expand board with new CEO

A new chief executive is being sought by AIM-listed stem cell specialist ReNeuron as it enters the next stage of its development. Current Chief Executive Michael Hunt will remain in the role until a replacement is recruited, when he will become Chief Financial Officer. Chairman Bryan Morton said:

Read more
23 Apr 2014 11:37

ReNeuron Seeking New Chief Executive, Current To Become Financial Officer

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday that it was appointing a new Chief Executive Officer to replace Michael Hunt, who will be moving into the role of Chief Financial Officer when a successor has been recruited. The company said that, as a result of the progress it has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.